key: cord-0322378-jtka8929
authors: Allicock, O. M.; Yolda-Carr, D.; Earnest, R.; Breban, M.; Vega, N.; Ott, I. M.; Kalinich, C.; Alpert, T.; Petrone, M.; Wyllie, A. L.
title: Method versatility in RNA extraction-free PCR detection of SARS-CoV-2 in saliva samples
date: 2021-12-30
journal: nan
DOI: 10.1101/2021.12.27.21268334
sha: 3dad2677a032f4ca83b3a51e8b07f8735dc29fe7
doc_id: 322378
cord_uid: jtka8929

Early in the pandemic, a simple, open-source, RNA extraction-free RT-qPCR protocol for SARS-CoV-2 detection in saliva was developed and made widely available. This simplified approach (SalivaDirect) requires only sample treatment with proteinase K prior to PCR testing. However, feedback from clinical laboratories highlighted a need for a flexible workflow that can be seamlessly integrated into their current health and safety requirements for the receiving and handling of potentially infectious samples. To address these varying needs, we explored additional pre-PCR workflows. We built upon the original SalivaDirect workflow to include an initial incubation step (95{degrees}C for 30 minutes, 95{degrees}C for 5 minutes or 65{degrees}C for 15 minutes) with or without addition of proteinase K. The limit of detection for the workflows tested did not significantly differ from that of the original SalivaDirect workflow. When tested on de-identified saliva samples from confirmed COVID-19 individuals, these workflows also produced comparable virus detection and assay sensitivities, as determined by RT-qPCR analysis. Exclusion of proteinase K did not negatively affect the sensitivity of the assay. The addition of multiple heat pretreatment options to the SalivaDirect protocol increases the accessibility of this cost-effective SARS-CoV-2 test as it gives diagnostic laboratories the flexibility to implement the workflow which best suits their safety protocols.

SARS-CoV-2 detection in saliva was developed and made widely available. This 23 simplified approach (SalivaDirect) requires only sample treatment with proteinase K prior 24 to PCR testing. However, feedback from clinical laboratories highlighted a need for a 25 flexible workflow that can be seamlessly integrated into their current health and safety 26 requirements for the receiving and handling of potentially infectious samples. To address 27 these varying needs, we explored additional pre-PCR workflows. We built upon the 28 original SalivaDirect workflow to include an initial incubation step (95°C for 30 minutes, 29 95°C for 5 minutes or 65°C for 15 minutes) with or without addition of proteinase K. The 30 limit of detection for the workflows tested did not significantly differ from that of the original 31

SalivaDirect workflow. When tested on de-identified saliva samples from confirmed 32 COVID-19 individuals, these workflows also produced comparable virus detection and 33 assay sensitivities, as determined by RT-qPCR analysis. Exclusion of proteinase K did 34 not negatively affect the sensitivity of the assay. The addition of multiple heat 35 pretreatment options to the SalivaDirect protocol increases the accessibility of this cost-36 effective SARS-CoV-2 test as it gives diagnostic laboratories the flexibility to implement 37 the workflow which best suits their safety protocols. 38 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

Almost two years after the emergence of SARS-CoV-2, diagnostic testing remains an 40 important mitigation strategy. As outbreaks and testing policies evolve and as screening 41 testing has emerged as a key feature enabling communities to safely re-open, labs have 42 had to adapt to the changing needs of their local communities. Throughout, this has often 43 required the rapid implementation of alternative or even novel strategies to meet testing 44 demands. However efforts have been hampered with staffing shortages, supply chain 45 disruptions and slow regulatory approval for alternative test protocols or testing 46 instrumentation. Combined, these challenges highlight a great need for alternative testing 47 strategies that a) utilize locally available and inexpensive testing materials, and b) are 48 easy to adopt in either existing or newly created COVID-19 testing laboratories. 49 50 Alternative testing strategies should fit seamlessly into an existing workflow of a 51 laboratory, while adhering to relevant biosafety and biosecurity requirements. Within the 52 limits imposed by the mandatory Laboratory Biosafety Guidelines for Handling and 53

Processing Specimens issued by governing bodies 1 , each laboratory has their own 54 protocols when it comes to the intake and processing of infectious agents. As such, 55 adopting additional protocols to help meet mass testing needs, with limited or no flexibility 56 in the reagents, kits or instrumentation permitted for use, can result in delayed test 57 implementation due to the additional investment required or supply chain disruptions. 58

In an effort to increase access to COVID-19 testing by minimizing test implementation 60 challenges, we developed a freely available, open-source saliva-based RT-qPCR 61 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 diagnostic assay (SalivaDirect) with a simplified and flexible workflow. Key to this 62 approach was obviating the need for sample collection by trained healthcare personnel, 63 removing the requirement for specific collection devices and transport media, while 64 validating reagents and instrumentation from multiple suppliers to enable laboratories to 65 utilize their existing infrastructure, or when needed, to help circumvent supply chain 66 disruptions. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 For the spiking experiments, the use of de-identified specimens from healthy or SARS- 95°C for 30 minutes) using a heating block or a thermocycler. After incubation the 101 samples were split into 2 aliquots; 10 μL was stored at 4°C until testing in RT-qPCR, and 102 50 μL was placed in a separate tube with 2.5 μL (50mg/mL) proteinase K (Thermo Fisher). 103

After vortexing for 1 minute, the samples were incubated at 95°C for 5 minutes to 104 inactivate the proteinase K. Following sample processing, 5 µL of the saliva lysates (either 105 stored at 4°C or treated with proteinase K) were tested using the SalivaDirect real-time 106 RT-qPCR assay 11 . This assay uses primers and probes from the US CDC, targeting the 107 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101/2021.12.27.21268334 doi: medRxiv preprint control 12 . The RT-qPCR was performed using the Luna Universal Probe One-Step RT-109 qPCR Kit (New England Biolabs) on the BioRad CFX96 Touch (BioRad, CA). A synthetic 110 SARS-CoV-2 RNA control from Twist Bioscience (San Francisco, CA) was diluted to 100 111 copies/µL and used as the positive control for N1. 112 113

We performed a limit of detection confirmation study to evaluate the sensitivity of SARS-115

CoV-2 detection when testing samples with a heat-pretreatment step. Samples were 116 prepared by spiking SARS-CoV-2-positive saliva from a healthcare worker diagnosed 117 with COVID-19 with a known virus concentration (3.7 x 10 4 copies/µL) into saliva samples 118 from healthy individuals (negative for SARS-CoV-2 RNA). Spiked saliva samples at 119 concentrations of 50, 25 and 12 copies/µL were tested in triplicate, and concentrations of 120 6, 3, and 1.5 copies/µL were tested with 20 individual replicates. All samples were tested 121 using the seven workflows depicted in Figure 1 . The limit of detection for each workflow 122 was determined to be the lowest concentration at which at least 19/20 replicates were 123 positive for SARS-CoV-2 (cycle threshold (Ct) value <40.0). 124 125

We validated each of the different workflows using 20 de-identified clinical saliva 127 specimens which previously tested positive for SARS-CoV-2 using the standard 128

SalivaDirect workflow ( Figure 1A ). Each sample was processed by each of the six 129 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The limit of detection (LOD) for the original SalivaDirect protocol (reagents and PCR 146 instrument, depending) is as few as 1.5 copies/μL 13 , with the formal LOD recorded at 12 147 copies/μL, reflecting the least sensitive combination of recommended reagents and 148 instruments 11 . To determine the LOD of the alternate workflows, we tested spiked saliva 149 samples at 50, 25 and 12 virus RNA copies/μL in triplicate, all of which were detected by 150 RT-qPCR (Table S1). We confirmed the LOD for each workflow by testing 20 replicates 151 of spiked saliva samples at lower viral copies (6, 3 and 1.5 virus RNA copies/μL). While 152 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10. 1101 /2021 all 20 of the individual replicates of the spiked samples at 6 virus RNA copies/μL tested 153 positive for each workflow (Figure 2, Table 1) , some workflows were more sensitive, with 154 workflows including a heat incubation step of 65°C for 15 minutes without proteinase K, 155 and 95°C for 5 minutes with or without proteinase K having a limit of detection of 3 virus 156 RNA copies/μL. 157

To investigate the agreement between each of the different workflows and the original 160

SalivaDirect protocol, 20 saliva samples which previously tested positive for SARS-CoV-161 2 by SalivaDirect (Ct value range 22.16 -38.71) were processed using each of the 162 different workflows. There was a median Ct difference in workflows of 0.92 to 6.08 across 163 each of the clinical samples ( Figure 3A) . Ct values from the N1 gene obtained from the 164 original saliva direct workflow correlated with each of the alternate workflows (Pearson r 165 > 0.9, p <0.0001) ( Figure S1 , Table S2 ). The workflow that was significantly less efficient 166 at detecting N1 gene than the original was 95°C for 30 minutes with the added proteinase 167 K step (ΔCt = 1.46, p < 0.001). 168

We also investigated the impact of proteinase K on the sensitivity of each workflow 170 ( Figure 3B) . While the addition of proteinase K made no difference when the samples 171 were first incubated at 95°C for 5 minutes, the addition of proteinase K following 172 incubation at 65°C for 15 minutes resulted in an increase in sensitivity (median difference 173

in Ct value = -0.53, p = 0.027). When the proteinase K was added following incubation at 174 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 In the current study we investigated the addition of thermal incubation prior to testing 199 saliva samples with the simplified RT-qPCR assay, SalivaDirect, and evaluated the effect 200 of heat pre-treatment on the sensitivity of SARS-CoV-2 detection. Although 56°C is 201 commonly used for inactivation of enveloped viruses 18 , higher temperatures have been 202 used for other coronaviruses 6 . More recently, it has been shown that SARS-CoV-2 viral 203 particles can be inactivated by incubating a sample at 65°C for 15 minutes and 95°C for 204 5 minutes before processing 7, 8, 19 , without loss of sensitivity in nasopharyngeal swabs 205 and sera 2, 7 . While in the current study, we did not confirm the inactivation of SARS-CoV-206 2 following heat pretreatment, the conditions selected were based on the literature 207 demonstrating the total inactivation of SARS-CoV-2, or, in the case of 95°C for 30 minutes 208 (workflow C), at the request of testing laboratories who were already utilizing this step 209 prior to testing by alternative methods. 210 211 For all workflows investigated, we found a limit of detection of 3 to 6 copies/μL. The 212 robustness of the detection of the N1 gene in saliva has been demonstrated previously, 213 with no significant decrease in sensitivity when exposed to moderate heat 10, 20 . 214

Additionally, proteinase K also did not significantly affect the overall sensitivity of detection 215 of the N1 gene (paired t test, p = 0.247). Rather, at the lower incubation temperature 216 (65°C for 15 minutes), addition of proteinase K marginally increased the sensitivity of 217 detection as compared to samples processed without proteinase K. It is possible that, 218 while 65°C alone can effectively inactivate SARS CoV-2, this is not as effective at 219

"extracting" all of the virus RNA for RT-qPCR detection. Conversely, the addition of the 220 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101/2021.12.27.21268334 doi: medRxiv preprint proteinase K step to samples incubated at 95°C for 30 minutes significantly decreased 221 the sensitivity of both N1 and RNAse P detection when compared to the original 222 SalivaDirect protocol. However, while RP is used as an internal control, the minor 223 differences observed would not affect the outcome of the assay. Proteinase K degrades 224

RNases and assists in preserving RNA integrity, hence it is commonly used in the 225 processing of samples for molecular assays, especially in various extraction-free 226 workflows 21, 22 . Extraction-free workflows with saliva is no exception, and has been 227 incorporated into many saliva-based extraction-free molecular assays 23-26 , including 228

The addition of alternate workflows to an already flexible testing framework further 231 support the rapid implementation of the SalivaDirect RT-qPCR assay in diagnostic and 232 research laboratories looking to improve access to SARS-CoV-2 testing in their local 233 communities. Importantly, with the addition of pre-treatment heat steps, these expanded 234 workflows help to prevent the exposure of laboratory personnel directly or indirectly 235 handling potentially SARS-CoV-2-infected samples, while providing flexibility of 236 adaptation into their existing standard operating procedures. One of the unique attributes 237 of SalivaDirect is it is validated with materials from multiple vendors, to minimize the risk 238 of supply chain issues. The option of omitting proteinase K treatment makes this flexible 239 framework even less vulnerable to supply shortages, and more affordable for laboratories 240 -and thus importantly, to their patients. This is especially important for the implementation 241 of mass testing strategies in resource-poor areas, or in low-to-middle income countries 242 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10. 1101 /2021 7.

Batéjat C, Grassin Q, Manuguerra J-C, Leclercq I: Heat inactivation of the severe 281 acute respiratory syndrome coronavirus 2. J Biosaf Biosecur 2021, 3:1-3. 282 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

CDC: Interim Laboratory Biosafety Guidelines for Handling and Processing

267 Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays

Inactivation of the 270 coronavirus that induces severe acute respiratory syndrome, SARS-CoV

273 Evaluation of SARS-Coronavirus Decontamination Procedures

Inactivation of coronaviruses by heat

Middle East respiratory syndrome coronavirus

CDC: Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-306

FDA: FDA authorizes first test to aid in detecting a type of herpes virus in newborns 311 called cytomegalovirus

announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-313 newborns-called-cytomegalovirus. Last Accessed 2021/12/21

Shakir 315 SM: Self-Collected Anterior Nasal and Saliva Specimens versus Health Care 316

Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-317

AI: Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis

SalivaSTAT: Direct-PCR and Pooling of Saliva Samples 326

Collected in Healthcare and Community Setting for SARS-CoV-2 Mass

Concentration of spiked saliva (virus RNA copies/µL) 65°C for 15 minutes 95°C for 5 minutes 95°C for 30 minutes With PK Without PK With PK Without PK With PK Without PK

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 18. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 30, 2021. ; https://doi.org/10. 1101 /2021 Tables 362 Table 1 Table S1 . processed without proteinase K (blue dots), and those with proteinase K (green dots). 398The area below the dotted line indicates the detection threshold for the N1 gene. Data 399 used to make this figure can be found in Table S2 . (*, p = 0.027; **, p = 0.009) 400Abbreviations: Ct, cycle threshold; ND, not detected; PK, proteinase K. 401 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 30, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021